March 15, 2002Journal of Clinical Oncology
Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol
Why the study?
Does doxorubicin by continuous infusion prevent cardiotoxicity compared to bolus infusion in children with high-risk acute lymphoblastic leukemia?
Population
121 children with high-risk acute lymphoblastic leukemia
Comparison
Doxorubicin 360 mg/m2 in 30-mg/m2 doses every 3… vs Doxorubicin 360 mg/m2 in 30-mg/m2 doses every 3…
Design
RCT, randomized
Authors
Discussion
Loading...
Member takes
Implication
Continuous infusion confers no cardioprotective benefit over bolus doxorubicin in pediatric ALL; challenges assumptions favoring prolonged infusion to limit LV dysfunction.
Structured PICO
Does doxorubicin by continuous infusion prevent cardiotoxicity compared to bolus infusion in children with high-risk acute lymphoblastic leukemia?
P
Population
121 children with high-risk acute lymphoblastic leukemia
I
Intervention
Doxorubicin 360 mg/m2 in 30-mg/m2 doses every 3 weeks by continuous infusion over 48 hours
C
Comparator
Doxorubicin 360 mg/m2 in 30-mg/m2 doses every 3 weeks by bolus within 1 hour
O
Outcome
Echocardiographic measures of left ventricular (LV) structure and function (z scores)surrogate
Continuous doxorubicin infusion over 48 hours does not offer a cardioprotective advantage over bolus infusion in children with high-risk acute lymphoblastic leukemia.
Cite This Study
Steven E. Lipshultz (2002) studied this question.